Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Isoglycemic Clamp · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 | ACTIVE_COMPARATOR | Part I of the trial |
| Part 2 | ACTIVE_COMPARATOR | Part II of the trial |
| Name | Type | Description |
|---|---|---|
| Isoglycemic Clamp | DRUG | Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2) |
| Comparator: insulin glargine | DRUG | Insulin glargine at 0.4 U/kg |
Inclusion Criteria: Part 1: * Patient is a male between 18 to 45 years of age (inclusive) at the prestudy (screening) visit * Patient has a clinical diagnosis of type 1 diabetes * Patient must have been treated with insulin since diagnosis and be on a stable dose of insulin * Patient has a Body Ma...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
Isoglycemic Clamp is an investigational small molecule being developed by Merck & Company, Inc. for the treatment of Diabetes. It is currently in Phase 1 clinical development. The drug is being studied for its pharmacodynamic and pharmacokinetic effects in patients with diabetes.
The molecular target of Isoglycemic Clamp has not been disclosed. It is a small molecule being developed for Diabetes, but its specific mechanism of action is not publicly available. The drug is currently in Phase 1 clinical trials.
Isoglycemic Clamp is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for the treatment of Diabetes.
Isoglycemic Clamp is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, with no active trials currently ongoing.
Isoglycemic Clamp has one completed clinical trial, NCT01152242, titled "Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)". This Phase 1 study enrolled 36 male participants aged 18 years and older with Diabetes. The trial was active-controlled but not randomized or double-blinded.
Isoglycemic Clamp is also known as 0000-168, as referenced in the clinical trial title NCT01152242. The trial evaluates the pharmacodynamic and pharmacokinetic variability of this basal insulin product in patients with Diabetes.